II. Indications
III. Dosing: Adults
- Start 2.5 mg orally twice daily
- Target: 5 to 10 mg/day divided twice daily
- Maximum: 20 mg/day (10 mg/day in the elderly)
IV. Mechanism
- See Dihydropyridine Calcium Channel Blocker
- Selectively inhibits vascular smooth Muscle Contraction and SA Node conduction
- Does not reduce cardiac contractility
- Does not affect AV Node conduction
V. Adverse Effects
- See Dihydropyridine Calcium Channel Blocker
- Less reflex Tachycardia than other agents due to selectivity
- Headache
- Peripheral Edema
- Flushing
VI. Safety
- Pregnancy Category C
- Unknown Safety in Lactation
VII. Metabolism
- Well absorbed, but high first pass metabolism
VIII. Resources
- Isradipine Capsule (DailyMed)
IX. References
- (2022) Presc Lett, Resource #381108, Comparison of Calcium Channel Blockers
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 70-1
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
Definition (MSH) | A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure. |
Definition (NCI) | A dihydropyridine calcium channel blockers with antihypertensive and vasodilator activities. Isradipine blocks the calcium entry through the calcium ion channels of coronary and peripheral vascular smooth muscle, thereby dilating coronary arteries and peripheral arterioles. This increases oxygen delivery due to an increased blood flow and reduces oxygen requirements due to decrease in total peripheral resistance. (NCI05) |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D017275 |
SnomedCT | 108533002, 386862002 |
English | Isradipine, 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, 3,5-Pyridinedicarboxylic Acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, Methyl 1-methylethyl Ester, Isopropyl methyl(+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate, isradipine (medication), isradipine, ISRADIPINE, Isradipine [Chemical/Ingredient], Isradipine (product), Isradipine (substance) |
Swedish | Isradipin |
Czech | isradipin |
Finnish | Isradipiini |
Russian | IZRADIPIN, ИЗРАДИПИН |
Japanese | イスラジピン |
Spanish | isradipino (sustancia), isradipino (producto), isradipino, isradipina, isradipina (producto), isradipina (sustancia), Isradipino |
Polish | Isradypina |
French | Isradipine |
German | Isradipin |
Italian | Isradipina |
Portuguese | Isradipino |
Ontology: Dynacirc (C0813618)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D017275 |
English | dynacirc, Dynacirc |